| Literature DB >> 28579481 |
Ross A Soo1, Emily C A Stone2, K Michael Cummings3, James R Jett4, John K Field5, Harry J M Groen6, James L Mulshine7, Yasushi Yatabe8, Lukas Bubendorf9, Sanja Dacic10, Ramon Rami-Porta11, Frank C Detterbeck12, Eric Lim13, Hisao Asamura14, Jessica Donington15, Heather A Wakelee16, Yi-Long Wu17, Kristin Higgins18, Suresh Senan19, Benjamin Solomon20, Dong-Wan Kim21, Melissa Johnson22, James C H Yang23, Lecia V Sequist24, Alice T Shaw24, Myung-Ju Ahn25, Daniel B Costa26, Jyoti D Patel27, Leora Horn28, Scott Gettinger29, Solange Peters30, Murry W Wynes31, Corinne Faivre-Finn32, Charles M Rudin33, Anne Tsao34, Paul Baas35, Ronan J Kelly36, Natasha B Leighl37, Giorgio V Scagliotti38, David R Gandara39, Fred R Hirsch40, David R Spigel22.
Abstract
Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas, including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for NSCLC, SCLC, and mesothelioma. Quality and value of care and perspectives on the future of lung cancer research and treatment have also been included in this concise review.Entities:
Keywords: Adjuvant therapy; Biomarkers; Cancer prevention; Immunotherapy; Malignant mesothelioma; Molecular diagnostics; NSCLC; Pathology; Radiotherapy; SCLC; Screening; Smoking cessation; Staging; Surgery; Targeted therapy; Value of therapy
Mesh：
Year: 2017 PMID： 28579481 DOI： 10.1016/j.jtho.2017.05.019
Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609